Praxis Precision Medicines (PRAX) shares are in focus after the biotech reported third quarter results that showed a wider net loss and a lower loss per share, while investors also weigh upcoming launch readiness updates for ulixacaltamide and relutrigine.
The latest earnings update and launch preparations arrive after a sharp move in Praxis Precision Medicines’ share price, with a 7-day share price return of 21.57% and a 30-day gain of 37.72% lifting year to date share price performance to 20.88%. That rebound comes after the stock declined 6.04% over the past 90 days, while long term investors are still sitting on an 88.56% 1-year total shareholder return and a very large 3-year total shareholder return above 20x. This pattern signals that momentum has recently picked up again as the market rethinks both opportunity and risk around its CNS pipeline.
Scan how Praxis Precision Medicines fits into the wider CNS and biotech opportunity set by comparing it with a curated list of 19 high quality undiscovered gems that present similar risk and reward trade-offs.
After a run this sharp in Praxis Precision Medicines, the key question is straightforward: Do the current launch ambitions and cash burn still leave the upside skewed toward buyers, or has the balance flipped?
Most Popular Narrative: 49% Undervalued
On the analyst consensus Narrative on Simply Wall St, Praxis Precision Medicines screens as significantly undervalued, with a fair value of $676.20 against a last close of $346.21. This frames a wide gap between modeled future earnings power and today’s share price.
Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.
See why 9 investors see Praxis Precision Medicines as 49% undervalued.
Result: Fair Value of $676.20 (UNDERVALUED)
Still, the Praxis Precision Medicines story could shift quickly if key EMERALD data disappoint, or if ulixacaltamide and relutrigine face unexpected regulatory setbacks.
Find out about the key risks to this Praxis Precision Medicines narrative.
Next Steps
Sentiment on Praxis Precision Medicines is clearly split. This is exactly why your own judgment matters more than ever right now. Weigh both the upside potential and the issues flagged in the data, then dig into the full balance of 2 key rewards and 1 important warning sign.
Looking for more Praxis Precision Medicines investment ideas?
If Praxis Precision Medicines has your attention now, consider broadening your watchlist with a few more focused ideas that could help sharpen your next move.
- Explore potential upside in quality companies that may be priced below their fundamentals by running the 32 high quality undervalued stocks.
- Prioritise resilience and capital preservation by using the 30 resilient stocks with low risk scores to filter for businesses with sturdier risk profiles.
- Strengthen your watchlist with balance sheets that may be better positioned to withstand shocks through the list of solid balance sheet and fundamentals (23 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com